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Abstract
Background: Vertebral osteomyelitis is a common manifestation of osteomyelitis in adults and associated with 
considerable morbidity. Limited data exist regarding hematogenous vertebral osteomyelitis. Our objective was to 
describe the epidemiology and management of hematogenous vertebral osteomyelitis.
Methods: We performed a 2-year retrospective cohort study of adult patients with hematogenous vertebral 
osteomyelitis at a tertiary care hospital.
Results: Seventy patients with hematogenous vertebral osteomyelitis were identified. The mean age was 59.7 years 
(±15.0) and 38 (54%) were male. Common comorbidities included diabetes (43%) and renal insufficiency (24%). 
Predisposing factors in the 30 days prior to admission included bacteremia (19%), skin/soft tissue infection (17%), and 
having an indwelling catheter (30%). Back pain was the most common symptom (87%). Seven (10%) patients 
presented with paraplegia. Among the 46 (66%) patients with a microbiological diagnosis, the most common 
organisms were methicillin-susceptible S. aureus [15 (33%) cases], and methicillin-resistant S. aureus [10 (22%)]. Among 
the 44 (63%) patients who had a diagnostic biopsy, open biopsy was more likely to result in pathogen recovery [14 
(93%) of 15 with open biopsy vs. 14 (48%) of 29 with needle biopsy; p = 0.003]. Sixteen (23%) patients required surgical 
intervention for therapeutic purposes during admission.
Conclusions: This is one of the largest series of hematogenous vertebral osteomyelitis. A microbiological diagnosis 
was made in only approximately two-thirds of cases. S. aureus was the most common causative organism, of which 
almost half the isolates were methicillin-resistant.
Background
Vertebral osteomyelitis, also termed spondylodiscitis, is a
common manifestation of osteomyelitis in adults [1,2]. It
encompasses both infection due to a contiguous source,
(i.e. post-surgical and trauma) and hematogenous spread
[3]. Despite significant differences in pathogenesis, stud-
ies on vertebral osteomyelitis often do not distinguish
between the specific infectious etiologies [4]. The preva-
lence of vertebral osteomyelitis appears to be increasing,
though this may be due to a variety of factors including
better diagnostic techniques, an aging and more immu-
nocompromised population, increasing indwelling device
use and intravenous drug use [5]. Hematogenous verte-
bral osteomyelitis is associated with significant morbidity
including prolonged antimicrobial therapy, risk of recur-
rence, decreased functional status, and paralysis [4,6].
Previous studies of hematogenous vertebral osteomyelitis
are limited by relatively small sample sizes [7] and were
performed prior to the dramatic increase of MRSA in the
community [8,9]. A more recent study suggests that the
microbiology of this disease may be changing [10].
We performed a retrospective cohort study of patients
with hematogenous vertebral osteomyelitis in an effort to
gain a better understanding of the current clinical presen-
tation, management and treatment of this disease entity.
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Methods
Setting
Barnes-Jewish Hospital (BJH), a 1250-bed teaching hos-
pital, is the largest hospital in Missouri, with a referral
base that includes the Saint Louis metropolitan area,
eastern Missouri and western Illinois.
Study design
We performed a two-year, retrospective cohort study of
patients admitted to Barnes-Jewish Hospital between
January 1, 2004 and December 31, 2005, and diagnosed
with hematogenous vertebral osteomyelitis. We utilized
the BJH Medical Informatics database to identify all dis-
charges with ICD-9-CM codes for vertebral osteomyeli-
tis, spondylodiscitis, disk infection, and epidural abscess
[epidural abscess (324.1 and 324.9), osteomyelitis of the
spine or unspecified site (730.28, 730.08, 730.2, 730.00),
and discitis (722.90, 722.91, 722.92, 722.93)]. Discharges
containing these ICD-9-CM codes were then reviewed to
determine if they met study criteria defined below. The
study was approved by the Washington University
Human Research Protection Office.
Inclusion and exclusion criteria
Patients ≥ 18 years old admitted to the hospital who pre-
sented with or developed hematogenous vertebral osteo-
myelitis as defined by characteristic radiographical
changes including decreased signal intensity in the verte-
bral body and disk and loss of endplate definition on T1
weighted images and increased signal intensity of the disk
and vertebral body on T2 weighted images. We excluded
patients with contiguous osteomyelitis due to decubitus
ulcers, trauma, and surgical site infection (defined as
infection within one year of spinal surgery). Stage I decu-
bitus ulcers were not considered a reason for exclusion.
Patients with incomplete medical records (n = 4) were
also excluded.
Data collection
We reviewed medical records of all the patients who met
study criteria. Medical records were reviewed for demo-
graphic information, comorbidities, antibiotic history,
presenting symptoms, vital signs and physical examina-
tion findings, diagnostic procedures, microbiology, and
medical and surgical treatment. Laboratory values and
temperature data within twenty-four hours of admission
were collected.
Definitions
Renal insufficiency was defined as serum creatinine of ≥ 2
mg/dL. Active malignancy was defined as having received
chemotherapy or radiation therapy for cancer in the pre-
vious six months. For coagulase-negative staphylococci
or other possible skin contaminants to be considered a
true pathogen, they had to be isolated from a sterilely
obtained bone biopsy and/or two or more blood cultures
drawn on separate occasions.
Statistical analysis
Data entry was performed using Microsoft Access and
Excel (Microsoft Corp., Redmond, WA) and data analysis
was performed using SPSS 14 (SPSS Inc., Chicago, IL).
Univariate comparisons among categorical variables were
performed using the χ2  test or Fisher's exact test, as
appropriate. Comparisons among continuous indepen-
dent variables were performed using Student's t test or
Mann Whitney U test, as appropriate. A two-sided p
value of < 0.05 was considered significant.
Results
Patient characteristics and clinical presentation
Of the 272 patients with ICD-9-CM codes of interest, 70
were identified as having hematogenous vertebral osteo-
myelitis and met study criteria (Table 1). The mean age
was 59.7 years (standard deviation ±15, range 44-74) and
38 patients were male (54.3%). Chronic renal insuffi-
ciency and diabetes mellitus were the leading comorbidi-
ties in our patient cohort. Thirteen (18.6%) patients
received chronic hemodialysis therapy. Seven patients
(10.0%) had received systemic corticosteroids in the
recent past, of which five had received treatment in the
last month.
Forty-six (65.7%) patients had a documented infection
at another site within the thirty days prior to admission.
Thirty-one (44.3%) patients had been transferred from an
outside hospital to our institution. Compared to patients
admitted directly to our hospital, patients transferred
from an outside hospital were more likely found to have a
history of documented pneumonia [6 (8.6%) transfer vs. 1
(1.4%) non-transfer, p = 0.03] or bacteremia [10 (14.3%)
transfer vs. 3 (4.3%) non-transfer, p = 0.01] in the thirty
days prior to admission. In terms of other predisposing
factors and signs, such as neurological deficits/paralysis,
there were no statistical differences observed between the
two groups.
The most frequently reported symptoms on admission
were back pain in 61 (87.1%) patients, weakness in 39
(55.7%), and fever in 32 (45.7%). Prior to admission, the
median duration of back pain was a median of 17.5 days
(range 1-365 days). The median duration of weakness was
14 days (range 1-120 days). The median duration of fever
was 6.5 days (range 1-30 days). Twenty-eight (40%)
patients in our cohort presented with a normal white
blood cell count. Of patients who had laboratory tests for
ESR and CRP (n = 58 and n = 40, respectively) performed,
only one patient had an ESR within normal limit and two
had normal CRP levels (Table 2).
A complete neurological exam was documented for 66
patients. Nine patients (12.9%) in our cohort were notedBhavan et al. BMC Infectious Diseases 2010, 10:158
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Table 1: Patient characteristics and clinical presentation in 70 cases of hematogenous vertebral osteomyelitis
Variable n (%)
Age (mean, ± standard deviation), years 59.7 (±15.0)
Male gender 38 (54%)
Caucasian race 44 (63%)
Body mass index (median, range), kg/m2 27.2 (13.4-80.6)
Transfer from outside hospital 31 (44%)
Comorbidities
Diabetes mellitus 30 (43%)
Degenerative joint disease 30 (43%)
Renal insufficiency (serum-creatinine > 2 mg/dl) 17 (24%)
History of spinal injury 12 (17%)
History of spinal surgery (>1 year ago) 10 (14%)
HIV infection 1 (1%)
Malignancy 1 (1%)
Solid organ transplant/Bone marrow transplant 1 (1%)
Procedures or infections in prior month
Urinary tract infection 14 (20%)
Indwelling catheter 21 (30%)
Bacteremia 13 (19%)
Skin or soft tissue infection 12 (17%)
Pneumonia 7 (10%)
Colonoscopy 2 (3%)
Dental procedure 2 (3%)
Reported symptoms
Back pain 61 (87%)Bhavan et al. BMC Infectious Diseases 2010, 10:158
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to have a normal neurological exam on admission
(Table1). Twenty patients (33.9%) had one neurological
deficit, sixteen (27.1%) had two deficits, and twenty-three
patients (39.0%) had three or more documented deficits.
Diagnostic evaluation
All 70 patients underwent radiological evaluation. The
most common radiological diagnoses were discitis
(75.7%), vertebral osteomyelitis (67.1%), epidural abscess
(35.7%), and paraspinal abscess (21.4%). The lumbar
spine was the most common location of infection
(47.1%), followed by the thoracic (28.6%) and cervical
spine (24.3%). In addition to radiographic and microbio-
logical findings, in 19 (27.1%) cases pathological findings
confirmed the diagnosis of vertebral osteomyelitis.
The Infectious Diseases service was consulted in 65
(92.9%) of cases to guide diagnostic procedures and ther-
apy. Neurosurgery was consulted in 54 (77.1%), and
orthopedic surgery in 11 (15.7%) cases.
Forty-six (66%) patients had a microbiological diagno-
sis made by bone biopsy and/or positive blood culture
(Table 3). Eighteen patients (26%) were diagnosed by
bone biopsy, 18 (26%) by blood culture, and an additional
10 (14%) cases had positive cultures both from bone and
blood specimens. Two out of 70 patients had polymicro-
bial infections. In cases with a microbiological diagnosis,
Staphylococcus aureus was isolated 54% of the time, with
40% of these cases being MRSA. Patients with a con-
firmed microbiological diagnosis by either bone or blood
culture were more likely to have an elevated temperature,
WBC and CRP level (Table 4).
Forty-four (63%) patients underwent needle or open
surgical biopsy of the spine as diagnostic evaluation
(Table 2). The median time from admission to bone
biopsy was 2.5 days (range 0-69). Among the patients
who had a diagnostic biopsy, open biopsy was more likely
to result in pathogen recovery [14 (93%) of 15 open biop-
sies vs. 14 (48%) of 29 needle biopsies; p = 0.003]. Sixteen
of 44 patients had culture-negative bone biopsies. In 18
cases, blood cultures were used to guide treatment and of
these patients 14 never underwent a bone biopsy.
Treatment and outcomes
Sixteen (23%) patients had a surgical procedure per-
formed during admission for therapeutic purposes as
indicated by neurological compromise, mechanical insta-
bility, etc. The most common surgical intervention was
laminectomy/discectomy in 10 (14%) patients, followed
by laminectomy/vertebral fusion in 5 (7%) patients and 1
patient (1%) underwent a corpectomy procedure.
Weakness 39 (56%)
Fever 32 (46%)
Radicular pain 24 (34%)
Sensory loss 20 (29%)
Weight loss 14 (20%)
Stool or urine incontinence 9 (13%)
Physical findings
Decreased deep tendon reflexes 46 (70%)
Impaired motor strength 40 (60%)
Sensory deficit 29 (44%)
Decreased rectal tone* 10 (14%)
Positive Babinski's sign 9 (13%)
NOTE. Data are presented as number (% of total) of cases, unless otherwise indicated. * Data available for 33 patients
Table 1: Patient characteristics and clinical presentation in 70 cases of hematogenous vertebral osteomyelitis (Continued)Bhavan et al. BMC Infectious Diseases 2010, 10:158
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Table 2: Diagnostic workup, treatment, and outcomes of 70 patients with hematogenous vertebral osteomyelitis
Variable n (%)
 Laboratory data*
WBC count within first 24 hours of admission (median, range), K/mm3 11.5 (3.3-42.7)
ESR (median, range), mm/h 93.5 (8-140)
CRP (median, range), mg/dL 88.7 (0.4-472)
Temperature within first 24 hours (median, range), °C 37.4 (36.6-40.0)
Diagnostic work-up
Blood culture on admission 60 (86%)
Needle biopsy 29 (41%)
Open biopsy 15 (21%)
Treatment
Any surgery performed 16 (23%)
Laminectomy/Discectomy 10 (14%)
Laminectomy/Fusion 5 (7%)
Corpectomy 1 (1%)
Outcomes
Paralysis developed during admission 1 (1%)
Median hospital length of stay (days, range) 12 (3-59)
Discharge location
Home or home health 25 (36%)
SNF/LTCF/Rehabilitation 41 (59%)
In-hospital mortality 3 (4%)
NOTE. Data are presented as number (% of total) of cases, unless otherwise indicated. * denotes maximum values. WBC = white blood cell count 
(normal range 3.8-9.8 per BJH laboratory medicine). CRP = C-reactive protein; data available for 40 patients (high risk => 3 mg/L per BJH laboratory 
medicine). ESR = erythrocyte sedimentation rate; data available for 58 patients (normal 0-35 per BJH laboratory medicine). SNF = skilled nursing 
facility. LTCF = long term care facility.Bhavan et al. BMC Infectious Diseases 2010, 10:158
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Fifty-five patients (78.6%) received antibiotic therapy
within 48 hours of admission (range 0-5 days). The most
frequently planned total duration of antibiotic therapy at
discharge was six weeks, and 11 (15.7%) patients were
scheduled to complete longer courses (7-12 weeks) of
antibiotics. When we examined patients with known pos-
itive blood cultures from an outside hospital prior to
transfer in combination with patients who had positive
blood or bone cultures at our hospital, we found that fifty
(71.4%) patients received treatment matching microbiol-
ogy susceptibility patterns for a recovered pathogen. Ade-
quate empirical treatment was administered to an
additional 17 (24.3%) patients without a microbiological
diagnosis and consisted of a combination of vancomycin
and either a third generation cephalosporin or a carbap-
enem.
A large number of patients presented with neurological
deficits, among whom six had a diagnosis of paralysis at
time of admission. Only one patient developed paralysis
during hospitalization, and all-cause mortality was low
(Table 2). The median length of hospital stay was 12 days
(range 3-59 days). The majority of patients were dis-
charged to a skilled nursing care/long term care facility.
Discussion
Our cohort represents one of the largest, single-center
studies of hematogenous vertebral osteomyelitis. Previ-
ous studies have often included surgical site infections
and other contiguous infections of the spine when
describing the epidemiology of vertebral osteomyelitis.
Hematogenous vertebral osteomyelitis as a separate
entity, however, has infrequently been studied [4,7,11,12].
These previous studies failed to clearly define exclusion
criteria regarding the presence of sacral decubitus ulcers,
which can be a cause of vertebral osteomyelitis [13]. In
our study, patients were excluded on the basis of having
decubitus ulcers stage II or greater. These patients were
the second most common subset of vertebral osteomyeli-
tis in our institution, after surgical site infections of the
spine.
In terms of patient characteristics, we found chronic
renal insufficiency and diabetes mellitus to be the most
frequent comorbidities among patients with hematoge-
nous vertebral osteomyelitis in our study population, sim-
ilar to what has been described in previous papers
[4,7,14]. The frequency of intravenous drug abuse as a
potential predisposing factor, however, was less common
as only 3 (4.3%) patients with history of IV drug abuse
admitted to drug use in the month prior to admission
compared to the 25% frequency reported by Hadjipavlou
[7]. The pathogenesis of hematogenous vertebral osteo-
myelitis implies the presence of bacteremia. Forty percent
of patients had bacteremia during the hospital stay and
19% of patients had a history of bacteremia in the month
prior to admission. Of the 28 patients with a positive
blood culture during their hospital stay, four patients had
a history of bacteremia in the month prior to admission.
Our findings are consistent with previously published
reports stating that blood cultures provide microbiologi-
cal diagnosis in 20-59% of cases [15]. Other potential
sources of spinal infection in the absence of detected bac-
teremia in the study cohort included urinary tract infec-
tions, skin and soft tissue infections, and pneumonia, as
reported previously [6].
The most frequently reported symptoms at presenta-
tion were back pain, weakness, and fever. Unlike previous
Table 3: Microbiology of 70 cases of hematogenous vertebral 
osteomyelitis from blood cultures and/or bone biopsies
Organism detected n (%)
MSSA 15 (21)
MRSA 10 (14)
Coagulase-negative staphylococci 7 (10)
Streptococcus spp. 4 (6)
E. coli 3 (4)
P. aeruginosa 2 (3)
E. faecalis 2 (3)
A. baumannii 1 (1)
E. cloacae 1 (1)
Propionibacterium sp. 1 (1)
No organism recovered 24 (34)
NOTE. Blood and/or bone cultures were performed in all 70 patients. 
MSSA = methicillin-susceptible Staphylococcus aureus. MRSA = 
methicillin-resistant S. aureus. There were five cases of coagulase-
negative staphylococci diagnosed with blood cultures, and two 
diagnosed by bone biopsies and blood cultures. The single 
Propionibacterium sp. infection was diagnosed by bone biopsy. There 
were two polymicrobial infections: one Staphylococcus aureus 
infection together with unidentifiable Gram-negative bacilli, and 
one coagulase-negative staphylococcal and Corynebacterium sp. 
infection.Bhavan et al. BMC Infectious Diseases 2010, 10:158
http://www.biomedcentral.com/1471-2334/10/158
Page 7 of 8
studies which described symptoms for greater than three
months prior to diagnosis [12], we report a shorter dura-
t i o n  o f  s y m p t o m s.  T h i s  m a y  b e  d u e  t o  s ev e r a l  f a c t o r s
including increased virulence of organisms, improved
diagnosis and imaging and possible misreporting in our
patient population, or may be related to increased access
to healthcare in an urban tertiary care setting.
Obtaining a microbiological diagnosis is crucial given
the need for prolonged antibiotic treatment and the
potential for increased cost, toxicity, and other adverse
events associated with broad-spectrum antibiotic use.
While biopsy is an important part of the diagnostic
workup of vertebral osteomyelitis, the microbiological
yield was only 40-60% in previous studies [7,16], similar
to the 64% yield (28/44 bone cultures) in our study. Sev-
eral mechanisms have been cited in the literature to
explain non-diagnostic biopsies, e.g. antibiotic adminis-
tration prior to biopsy, poor sampling technique, and the
resolution of infection [7]. In 26% (18 out of 70) of our
cases, blood culture results alone were used to guide
therapy in the absence of positive results from bone
biopsy.
Longitudinal data from the 1990's show S. aureus as an
increasing cause of hematogenous vertebral osteomyelitis
[17]. In contrast to previous studies [11], we noticed a
higher percentage of methicillin-resistant Staphylococcus
aureus. We observed 45% of our S. aureus isolates to be
methicillin-resistant. This corresponds to an increase in
methicillin-resistant  Staphylococcus aureus bacteremia
over the last decade [18]. This, along with our finding that
15% (7 of 46) of microbiologically diagnosed infections
were due to coagulase-negative Staphylococcus, under-
scores the need for including antimicrobial coverage
against methicillin-resistant Gram-positive bacteria as
part of empirical regimens. Recent evidence of higher
vancomycin MIC levels in MRSA isolates must be taken
into account to assure adequate dosing of vancomycin to
overcome these higher MIC levels in circulating strains
[19].
There are a few limitations to this study. We used a ret-
rospective design and therefore may have missed undoc-
umented predisposing factors. ICD-9-CM codes were
used to identify cases and we may have missed cases
which were misclassified as a result. The data is derived
from one tertiary care center, which may limit generaliz-
ability. Long-term outcomes of hematogenous vertebral
osteomyelitis, for example functional status after dis-
charge, and treatment outcomes could not be obtained
on this cohort. Among the strengths of this study are the
stringent use of exclusion criteria to define our patient
population and the size of the study. This is one of the
largest single-center cohorts of hematogenous vertebral
osteomyelitis reported to date.
Conclusions
In summary, we report descriptive data from a retrospec-
tive cohort of hematogenous vertebral osteomyelitis. We
observed that only two-thirds of patients had a microbio-
logical diagnosis confirmed. MRSA was isolated in a sub-
stantial proportion of cases and more frequently than
what has been previously published. This has important
implications for empirical treatment in the absence of
specific microbiological diagnosis, which should include
antimicrobials with activity against MRSA. Typical symp-
toms of infection were often absent in our cohort. Signs
of fever and leukocytosis were not reliable in establishing
the diagnosis of hematogenous vertebral osteomyelitis,
and patients often only presented with symptoms of
chronic back pain. The lack of signs which are usually
indicative of infection may confuse the clinical picture
and cause delays in diagnosis. Delays in diagnosis are
associated with adverse outcomes [6]. It is important for
Table 4: Comparison of hematogenous vertebral osteomyelitis patients based on presence of a microbiological diagnosis
Variable Microbiological diagnosis n = 46 No microbiological diagnosis n = 24 p value
Mean age (±SD) 57.5 (±15.5) 63.9 (±13.3) 0.08
Diabetes mellitus 18 (39.1%) 12 (50.0%) 0.4
Renal insufficiency 12 (26.1%) 5 (20.8%) 0.6
Bacteremia, last 30 days 7 (15.2%) 6 (25.0%) 0.3
History of indwelling catheter, last 30 days 12 (26.1%) 9 (37.5%) 0.3
Maximum temperature at admission (±SD), °C 38.0 (±0.8) 37.3 (±0.7) <0.001
Maximum WBC at admission (±SD), K/m m3 15.1 (±9.2) 9.4 (±4.8) 0.003
CRP at admission (±SD), mg/dL 132.2 (±107.4) 75.3(±112.2) 0.04
ESR at admission (±SD), mm/h 89.5 (32.4%) 83.6 (36.6%) 0.6
NOTE. SD = standard deviation. WBC = white blood cell count. CRP = C-reactive protein. ESR = erythrocyte sedimentation rate.Bhavan et al. BMC Infectious Diseases 2010, 10:158
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physicians to maintain a heightened level of suspicion for
osteomyelitis in the setting of persistent back pain and
any changes in neurological exam to initiate appropriate
laboratory and radiologic evaluations in order to make a
timely diagnosis.
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